Follistatin Gene Therapy Longevity Clinics: What Buyers Should Know Before Paying

If you are searching for a follistatin gene therapy longevity clinic, the first thing to know is simple: commercial availability is not the same as an approved longevity treatment.

Follistatin gene therapy is being marketed for lean mass, fat reduction, performance, and biological-age claims. Minicircle describes its FST-344 therapy as a plasmid gene therapy delivered by subcutaneous injection, with non-heritable effects that may last about one year, and says it is available through select clinics.¹ Its FAQ also says the therapy is investigational and has not yet been approved by the U.S. Food and Drug Administration.²

That combination matters. A buyer can be looking at a real biological mechanism, a real commercial offer, and a real clinical-trial listing while still being far from a proven anti-aging therapy.

This guide is not an argument that follistatin biology is fake. It is an argument for adult supervision. The question is not “does this sound futuristic?” The question is: what exactly is being offered, under what regulatory pathway, with what evidence, and what happens if something goes wrong?

What is follistatin gene therapy?

Follistatin is a protein involved in muscle biology partly because it can bind and inhibit myostatin, a signaling protein that limits muscle growth. Myostatin and follistatin are legitimate research topics in sarcopenia, muscle wasting, and body-composition biology.³

The clinic-facing version is different from a supplement or ordinary injection. Minicircle describes a nonviral plasmid approach: circular DNA instructions are delivered so cells temporarily produce a therapeutic protein, without integrating into chromosomes.¹² On the commercial page, the claimed treatment pathway is contact a clinic, complete testing, receive therapy by subcutaneous injection, and track results through a portal.¹

That does not make the therapy equivalent to an approved drug. It means the buyer should separate four layers:

1. Mechanism: follistatin can influence myostatin and muscle-related pathways.
2. Delivery: a plasmid gene-therapy platform is being used to prompt protein expression.
3. Clinical evidence: the public human-trial record is early and limited.
4. Regulation: approval depends on product, indication, jurisdiction, trial oversight, and marketing claims.

Those layers are often blurred in longevity marketing. A serious clinic should keep them separate.

What is being claimed commercially?

Minicircle’s FST-344 page says the therapy can increase lean mass and decrease fat, is administered by subcutaneous injection, is non-heritable, lasts about a year, and is available at select clinics.¹ The page also presents three-month outcome claims, including no serious adverse events, lean-mass increase, body-fat reduction, and epigenetic-age reduction in older patients, with a note that individual results may vary.¹

Its FAQ gives more useful buyer context. It says FST therapy is available through clinical partners, that Minicircle is preparing clinical-trial data for publication, that approximately 500 participants had received FST therapy as of April 2025, and that the therapy is investigational and not FDA approved.²

The careful reading is this: the company is openly making commercial and investigational claims, but published, independently reviewed, long-term human evidence is still the missing piece for a buyer deciding whether to pay.

What does the ClinicalTrials.gov listing show?

The public trial record for NCT07285629 is titled “Safety and Efficacy of Klotho and Follistatin Gene Therapy.” The official title describes injectable combination klotho and follistatin plasmid gene therapy in humans as an interventional, non-placebo-controlled pilot phase study.⁴

The design is the crucial part. The record lists:

• Status: recruiting.
• Phase: early phase 1.
• Sponsor: Minicircle.
• Enrollment: estimated 30 participants.
• Design: single group, non-placebo-controlled, no masking.
• Intervention: nonviral plasmid-delivered follistatin and klotho gene therapy.
• Primary outcomes: serum alpha-klotho, serum follistatin, and treatment-emergent adverse events.
• Safety follow-up in the primary adverse-event outcome: within one week, then one, two, and three months after treatment.⁴

The record also includes a jurisdiction detail that buyers should not miss: the detailed description says the investigational product will be administered at a site outside the United States that is not under FDA jurisdiction, while the U.S. site is limited to non-treatment pre/post outcome assessments such as cognitive testing or blood sample collection.⁴

That is useful evidence context, not proof of rejuvenation. A single-arm early-phase pilot can help generate safety and biomarker signals. It cannot, by itself, prove reduced mortality, disease prevention, durable safety, or a standard longevity-clinic treatment.

The listing also includes secondary outcomes such as quality-of-life scores, cognitive tests, physical-performance tests, inflammation markers, myostatin, IGF-1, and whole-blood DNA methylation biological-age estimates.⁴ Those may be interesting. They are not the same as validated clinical longevity endpoints.

It is also too early to read a three-month adverse-event window as long-term safety. FDA guidance on human gene therapy long-term follow-up explains that some gene therapy products are designed to create permanent or long-acting changes, so subjects may need extended monitoring for delayed adverse events.⁵ Even if a plasmid platform is described as non-integrating and temporary, a buyer should still ask what delayed-event surveillance exists beyond the initial follow-up period.

What the evidence does and does not show

Evidence layer	What it supports	What it does not prove
Minicircle commercial page and FAQ	The product is being marketed, described as nonviral plasmid therapy, and offered through partner clinics; the company also says it is investigational and not FDA approved.12	It does not prove independent efficacy, regulatory approval, or durable safety.
ClinicalTrials.gov NCT07285629	A recruiting early-phase pilot is publicly listed, with biomarker, safety, performance, cognition, and methylation outcomes.4	It does not prove anti-aging efficacy, mortality benefit, disease prevention, or lawful consumer marketing.
FDA approved gene therapy list	FDA-approved gene therapies exist for specific products and indications.6	It does not list follistatin, klotho, or Minicircle as approved products in the checked FDA page.
Follistatin/myostatin biology	Follistatin and myostatin are legitimate muscle-biology and sarcopenia research topics.3	It does not validate commercial plasmid gene therapy for healthy adults.
EMA/ATMP framework	Gene therapy falls inside a serious advanced-therapy regulatory frame in Europe.7	It does not make a specific medical-tourism offer legitimate without product- and jurisdiction-specific authorization.

For similar buyer-safety framing, see our guides to partial epigenetic reprogramming trials, peptide therapy regulation, and exosome therapy evidence and red flags.

What does FDA approval actually mean here?

The FDA maintains a public page of approved cellular and gene therapy products. As checked for this article on June 27, 2026, that page listed approved products such as ABECMA, ADSTILADRIN, CASGEVY, ELEVIDYS, HEMGENIX, KYMRIAH, LUXTURNA, ROCTAVIAN, YESCARTA, ZOLGENSMA, and others, but did not list follistatin, klotho, or Minicircle.⁶

That distinction matters because “gene therapy exists” is not the same as “this gene therapy is approved for longevity.” Approved gene therapies are typically tied to specific products, manufacturers, diseases, indications, dosing, labels, risk controls, and post-market monitoring. Disease-focused approvals cannot be generalized to healthy adults paying for performance or anti-aging claims.

The FDA’s patient page on regenerative medicine is also relevant because it warns that regenerative products require FDA licensure or approval before consumer marketing and generally require FDA oversight in a clinical trial before approval. It also warns that ClinicalTrials.gov registration or FDA establishment/product listing does not mean a product is legally marketed.⁸

For a U.S. buyer, the practical question is not whether a clinic can say “clinical trial” or “registered.” It is whether the exact product and exact use are FDA approved, part of an FDA-overseen investigational pathway, or being sold outside that framework.

What about Europe and medical tourism?

Europe is not a loophole category. The European Medicines Agency classifies advanced therapy medicinal products as including gene therapy medicines, somatic-cell therapy medicines, and tissue-engineered medicines. EMA says advanced therapy medicines are authorised centrally through the agency, and it continues to monitor safety and efficacy after approval and marketing.⁷

EMA and European medicines authorities also warn about unregulated advanced therapies. The warning signs include providers marketing a product as experimental while using it outside an authorised clinical trial, inability to confirm EMA or national-authority approval, and benefit claims that exceed approved treatments without supporting medical literature.⁹

For medical-tourism buyers, the lesson is not “avoid every clinic outside your home country.” It is: ask the regulatory question in the country where the injection happens, in the country where the product is manufactured, and in the country where the company is marketing to you.

Buyer checklist before paying

Before paying for follistatin gene therapy through a longevity clinic or partner provider, ask for written answers to these questions:

1. Is the product approved for this specific use in the jurisdiction where it will be administered?
2. If not approved, is this part of an authorized clinical trial or another named investigational pathway?
3. Who is the sponsor, who is the treating physician, and who is medically accountable after you leave?
4. What independent ethics, regulator, or IRB oversight applies?
5. What product is being injected, who manufactures it, and what batch testing, sterility testing, and chain-of-custody records exist?
6. What are the inclusion and exclusion criteria, especially for cancer history, autoimmune disease, kidney or liver disease, immune suppression, pregnancy, anticoagulant or antiplatelet use, and medication interactions?
7. What adverse-event reporting pathway is used, and who pays for complications?
8. What follow-up is included at one week, one month, three months, one year, and beyond?
9. Which outcomes are clinical, which are biomarkers, and which are exploratory?
10. What is the total itemized price, including testing, travel, physician time, product fee, portal access, follow-up labs, and complication coverage?
11. Are there refund terms if treatment is delayed, canceled, or contraindicated after screening?
12. Is the gene therapy bundled with peptides, exosomes, stem cells, hormones, or supplements, and what is the medical rationale for each add-on?
13. What claim would make the clinic refuse treatment?

That last question is revealing. A responsible clinic should be able to say no.

Red flags in follistatin gene therapy marketing

Be cautious when a clinic or partner provider leans on any of these claims:

• “FDA approval is not relevant because this is not a drug.”
• “ClinicalTrials.gov proves the therapy works.”
• “Epigenetic-age reduction means rejuvenation.”
• “No severe adverse events so far” without long-term follow-up and denominator detail.
• “Non-integrating” used as if it means no meaningful risk.
• Testimonials used as proof of efficacy.
• No named physician responsible for follow-up.
• No written contraindication screen.
• No clear adverse-event reporting route.
• Pressure to combine gene therapy with peptides, exosomes, hormones, or stem-cell packages without a specific medical rationale.

If a clinic sells certainty before it explains uncertainty, the sales process is ahead of the medicine.

How serious longevity clinics should frame this

Follistatin gene therapy should be framed as investigational, not as a standard longevity-clinic service. The responsible role for a clinic is education, trial literacy, risk screening, and referral only when the pathway is legitimate and the patient understands the evidence ceiling.

Diagnostic-first clinics such as Human Longevity Inc. and hospital-style executive-health programs such as Cleveland Clinic Executive Health illustrate the opposite end of the buyer spectrum: more emphasis on risk detection and specialist follow-up than on selling experimental interventions. Broader residential programs such as Progevita can still be useful comparison points for medical travel, but buyers should judge every advanced therapy by the same standard: evidence, regulation, physician accountability, and follow-up.

For side-by-side research, use WLC’s clinic comparison tool, rankings, and Find Your Clinic wizard. If you are specifically evaluating advanced therapies, also read our longevity clinic regulation guide, clinic standards guide, and longevity clinic cost guide.

Bottom line

Follistatin gene therapy is scientifically interesting and commercially available through some channels. It is not a proven, approved longevity treatment.

The buyer-protection standard is simple: mechanism is not medicine, access is not validation, biomarkers are not clinical outcomes, and trial registration is not approval. A credible longevity clinic should be able to explain all four points before asking you to pay.

If the answer is vague, wait. The safest interpretation of early gene-therapy offers in longevity is not “breakthrough” or “scam.” It is “investigational until proven otherwise.”

FAQ

Is follistatin gene therapy FDA approved for longevity?

No. As of this review, the FDA approved cellular and gene therapy products page did not list follistatin, klotho, or Minicircle, and Minicircle’s own FAQ describes its gene therapy as investigational and not yet FDA approved.²⁶

Does ClinicalTrials.gov prove the therapy works?

No. ClinicalTrials.gov registration is useful transparency, but the FDA warns that a ClinicalTrials.gov listing does not mean a product is legally marketed.⁸ The current public study record is early phase 1, single-group, non-placebo-controlled, and short-follow-up.⁴

Is nonviral plasmid therapy safer than viral gene therapy?

Not automatically. Nonviral, non-integrating delivery may reduce some theoretical risks, but safety still depends on product quality, dose, immune response, patient selection, monitoring, adverse-event reporting, and long-term follow-up.

Should I avoid every clinic that discusses follistatin?

No. Discussion is not the problem. The problem is selling broad anti-aging outcomes as if they were proven. A credible clinic can explain the mechanism, regulatory status, trial limits, contraindications, and reasons not to treat.

What is a better first step?

Start with a comprehensive medical risk assessment, body-composition measurement, exercise prescription, metabolic optimization, sleep evaluation, and guideline-based prevention. Experimental gene therapy should not be the first paid step in a longevity plan. For adjacent failures and lessons, see our review of senolytics and clinic claims.

---

Related reading:

• Partial Epigenetic Reprogramming Human Trials and Longevity Clinics
• Peptide Therapy at Longevity Clinics: Legal Reality, Evidence, and What to Ask Before Booking
• Exosome Therapy at Longevity Clinics: Evidence, Regulation, Costs, and Red Flags
• Are Longevity Clinics Regulated?

Footnotes

1. Minicircle. Follistatin Gene Therapy (FST-344), accessed June 27, 2026. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶

2. Minicircle. FAQs, accessed June 27, 2026. ↩ ↩² ↩³ ↩⁴ ↩⁵

3. Chakaroun R, et al. Myostatin and Follistatin-New Kids on the Block in the Diagnosis of Sarcopenia in IBD and Possible Therapeutic Implications. Biomedicines. 2021;9(10):1301. doi:10.3390/biomedicines9101301. ↩ ↩²

4. ClinicalTrials.gov. Safety and Efficacy of Klotho and Follistatin Gene Therapy, NCT07285629, accessed June 27, 2026. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶

5. U.S. Food and Drug Administration. Long Term Follow-up After Administration of Human Gene Therapy Products, January 2020. ↩

6. U.S. Food and Drug Administration. Approved Cellular and Gene Therapy Products, accessed June 27, 2026. ↩ ↩² ↩³

7. European Medicines Agency. Advanced therapy medicinal products: Overview, accessed June 27, 2026. ↩ ↩²

8. U.S. Food and Drug Administration. Important Patient and Consumer Information About Regenerative Medicine Therapies, June 3, 2021. ↩ ↩²

9. European Medicines Agency and Heads of Medicines Agencies. Unregulated advanced therapy medicinal products pose serious risks to health, April 28, 2025. ↩